
http://eprints.gla.ac.uk/59150/

Deposited on: 19 January 2012
The Virtual International Stroke Trials Archive

Myzoon Ali, MRes; Philip M.W. Bath, MD, FRCP; John Curram, PhD; Stephen M. Davis, MD, FRCP, FRACP; Hans-Christoph Diener, MD; Geoffrey A. Donnan, MD; Marc Fisher, MD; Barbara A. Gregson, BSc, PhD; James Grotta, MD; Werner Hacke, MD, PhD; Michael G. Hennerici, MD; Marc Hommel, MD; Markku Kaste, PhD, MD; John R. Marler, MD; Ralph L. Sacco, MD, MS; Philip Teal, MD; Nils-Gunnar Wahlgren, MD, PhD; Steven Warach, MD, PhD; Christopher J. Weir, PhD; Kennedy R. Lees, MD, FRCP

Background and Purpose—Stroke has global importance and it causes an increasing amount of human suffering and economic burden, but its management is far from optimal. The unsuccessful outcome of several research programs highlights the need for reliable data on which to plan future clinical trials. The Virtual International Stroke Trials Archive aims to aid the planning of clinical trials by collating and providing access to a rich resource of patient data to perform exploratory analyses.

Methods—Data were contributed by the principal investigators of numerous trials from the past 16 years. These data have been centrally collated and are available for anonymized analysis and hypothesis testing.

Results—Currently, the Virtual International Stroke Trials Archive contains 21 trials. There are data on >15 000 patients with both ischemic and hemorrhagic stroke. Ages range between 18 and 103 years, with a mean age of 69±12 years. Outcome measures include the Barthel Index, Scandinavian Stroke Scale, National Institutes of Health Stroke Scale, Orgogozo Scale, and modified Rankin Scale. Medical history and onset-to-treatment time are readily available, and computed tomography lesion data are available for selected trials.

Conclusions—This resource has the potential to influence clinical trial design and implementation through data analyses that inform planning. (Stroke. 2007;38:1905-1910.)

Key Words: clinical trials ■ trial design ■ natural history ■ database ■ modified Rankin Scale ■ National Institutes of Health Stroke Scale

Stroke is a major cause of mortality and severe disability in developed countries and has immense financial and social implications. Stroke management is estimated to cost the United States alone between $30 and $40 billion per year. After the age of 55, the risk of stroke almost doubles with each successive decade, further contributing to the financial burden of stroke as the population ages.

The development of drugs for clinical use in acute stroke has remained slow since the licensing of recombinant tissue-type plasminogen activator. Drugs such as pro-urokinase and ancrod, which seemed promising, have yet to be approved for marketing. Similarly, translating the success of neuroprotective agents in animal models or phase II trials into efficacy in phase III trials has been troublesome. With the exception of recombinant tissue-type plasminogen activator and, arguably, recombinant factor VII, there has been little impact on clinical practice. The failure of many trials to confirm efficacy has generated a need for reliable data on which to plan future trials.

Many studies worldwide have investigated the risk factors, etiology, geographic occurrence, ethnic disparity, and potential benefits of treatment regimens for stroke. The data sets from such studies reside in industry and academic archives long after the studies were published, but the
importance of the information contained within them is often underestimated.

By collating these data sets, a large and rich pool of information can be used for novel analysis of the natural history of homogeneous subgroups of stroke patients. This wealth of valuable information could inform the design of future randomized clinical trials. It could also allow testing of specific hypotheses. The Virtual International Stroke Trials Archive (VISTA) was set up in the spirit of contributing to mutually beneficial ventures to aid progress and breakthroughs in stroke clinical trials.

**Methods**

**Aims of VISTA**

VISTA has been established to promote excellence in stroke care and trial design. It is a collaborative venture involving clinical scientists from numerous international groups with experience in designing and conducting clinical trials in acute stroke. The main aim of VISTA is to facilitate the planning of randomized clinical trials. Through the collation and categorization of numerous clinical trials, the VISTA collaboration seeks to bring together under one umbrella large data sets that would have otherwise ordinarily been left dormant within university and industry archives. The VISTA database does not sanction reanalysis of any trial data that will test treatment effects; rather, it provides an unrivaled opportunity to access a large volume of patient data on which to perform novel exploratory analyses that would ultimately aid clinical trial design and development. This represents a major international resource, and the background and methods of data compilation are detailed here both to encourage potential collaborators to develop proposals for future analysis and to facilitate citation of the methodology in their reports.

**Establishment of VISTA**

Previous reluctance to amass data in this way was related to issues such as patient confidentiality, commercial sensitivity, reliability of data, authorship or intellectual property of a particular study, and its scientific merit. Similarly, investigators were apprehensive about the loss of control over the potential use or misuse of such data. These issues have been addressed through stringent guidelines detailing the handling of confidential patient information, ethics, representation, and publication. A Steering Committee comprising principal investigators from the contributing trials was established to judge the scientific merit and approve the proposed uses of trial data. The criteria used in this process include assessment of originality, scientific quality, potential for value to the wider scientific community, and publication potential. The data also require secure storage and restriction of access to authorized individuals only. Strict criteria have been implemented to ensure data protection. These detail the VISTA constitution, eligibility criteria, promotion, data storage, compatibility, and documentation.

**Policy**

VISTA has been designed to improve stroke care and trial design without favoring a particular organization, sponsor, or individual group. Membership in VISTA is therefore open to all trials and registries that meet the eligibility criteria, and the results of analyses carried out with the use of this resource should be used for the benefit of the wider population in academia, clinics, and industry. Membership is granted to trials and organizations rather than to individuals, and each organization should be represented on the Steering Committee by a named individual, usually the principal investigator.

**Selection of Trials**

The criteria for trial entry into VISTA are summarized in Table 1. Setting entry requirements and eligibility criteria for VISTA facilitates data compatibility and validity of analyses. However, data sets that do not completely conform to all of the criteria may still be considered for entry into VISTA: the intention is to be inclusive.

**Data Storage and Documentation**

The data are stored at the Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK. Trial representatives also have the option to retain their own converted or annotated data and merely to provide the data to investigators at the time of agreed analyses. VISTA holds only anonymized data, as the majority of the informed consent and institutional review board approvals that have been gathered restrict storage and transmission to anonymized data. Within analyses, data are also masked with respect to trial source.

The issue of data compatibility is addressed by the conversion of all data sets into a standardized form by use of the SAS 9.1 statistical package (SAS Institute, Inc). SAS 9.1 permits transfer and import of data in other formats such as Microsoft Excel, Access, SPSS, and other versions of SAS. The issues of data comparability have also been addressed through documentation of variables and the inclusion of data dictionaries alongside trials to explain the type, range, and units of each variable.

**Promotion of VISTA**

In its nascent phase, VISTA was promoted through word of mouth; however, VISTA now accepts the submission of proposals and the transfer of data electronically. A web portal encourages investigators to propose projects to be performed with VISTA. Anonymized data are accessible to examine whether the resource has the ability to accommodate specific end points or variables, and potential investigators may use the site to select and request specific variables for their proposed project.

The website also provides a forum through which the Steering Committee can review proposed projects to assess their viability, scientific merit, and relevance to VISTA aims. After acceptance of a written proposal, data are compiled and anonymized and can be sent through a secure web space to the investigator for local analysis, or analyses can be carried out centrally under the direction of the proposing author(s). VISTA actively encourages participation and inclusion of new collaborators through its website. An efficient approach for data transfer has the potential to encourage new partnerships and to reduce time frames of research projects.

**Content of VISTA**

Description of the contents of VISTA was integral to promotion of the database as a clinical resource. Data dictionaries are available for most trials in VISTA, but in some cases, additional information has been sought to clarify certain variables. Table 2 shows summary statistics on data held within VISTA as of September 20, 2006. Recruitment into VISTA is ongoing, and this table displays only...
those trials containing >100 patients in published or unpublished studies.

As of September 2006, the VISTA database contains information from 21 trials that met the VISTA criteria (Table 3), with individual data on >15,000 patients. Accumulation of these data took several years and involved collaborations among medical health professionals, trial coordinators in industry, and statisticians worldwide.

Twenty trials contain data on patients who experienced an ischemic stroke; 7 trials also contain data on patients who experienced an intracerebral hemorrhage. Currently, data are held for 13,029 patients with index ischemic stroke and for 1202 patients with index intracerebral hemorrhage.

VISTA contains data on patients between 18 and 103 years old, with data on 8129 men and 6897 women (Table 2). Patient data also include 90-day Scandinavian Stroke Scale; Barthel Index; modified Rankin Scale; National Institutes of Health Stroke Scale; and Orgogozo, Mathews, and European Stroke Scales. All 21 trials in the archive include the Barthel Index as a means of classifying functional ability after stroke; 10 trials include the National Institutes of Health Stroke Scale; 8 trials include the Scandinavian Stroke Scale; 3 describe the original Rankin Scale; and 12 have used the modified version. Sixteen of these 21 trials in the archive have a primary end point at 3 months, and 4 trials continued follow-up to 6 months. One trial ended at 21 days (Table 4). Measures of the SF-36 Health Survey, Orgogozo, Glasgow Coma Score, and European Stroke Scales are also selectively available.

Additional baseline data are available, including computed tomography imaging indicating the nature and cause of the stroke, hemispheric location, any corresponding midline shift, handedness of the patient, and evolution of the infarct or hemorrhagic transformation. Medical histories are also available, including such items as incidence of prior stroke or myocardial infarction, smoking history, and presence of diabetes and hypertension. The date of stroke onset, time between ictus and intervention, race, height, weight, and baseline blood pressure are also available for selected trials. Table 3 describes the treatments used in the trials contained within VISTA. However, trial treatment data are concealed during analyses to prevent identification of individual trials or reanalysis of therapeutic effect. Control group data alone are also available for some studies.

### Discussion

There have been limited developments in the transition between animal studies and clinical application of new therapies for stroke. More than 4000 published articles have described the potential efficacy of drugs for stroke therapy. However, with the exclusion of a few drugs, none have had a bearing on clinical practice, and only 2 promising candidates are waiting in the wings (NXY-05914 and citicoline15). Trial design has altered little over the years, yet it is clear that we are not yet routinely applying optimal selection criteria, end-point choices, or analysis approaches.16,17 VISTA facilitates access to a wide range of patient data from randomized trials and should further promote the effective design of future clinical trials.

For each case in VISTA, we can examine the relation between baseline prognostic factors, including concomitant treatments, and outcome measures. Thus, natural history analyses can be adjusted for many covariates. Investigators can specify whether their data set contains placebo and/or treatment group data, and, if necessary, these data can be used to conduct sensitivity analyses with output made available to VISTA investigators only in a form that does not compromise the anonymity of the trial(s).

---

**TABLE 2. Summary of Demography Statistics**

<table>
<thead>
<tr>
<th>Variable</th>
<th>No. of Records</th>
<th>Frequency Counts</th>
<th>Description (Median [IQR]*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>15,139</td>
<td>...</td>
<td>71 [62, 78]</td>
</tr>
<tr>
<td>Sex</td>
<td>15,026</td>
<td>M=8129, F=6897</td>
<td>...</td>
</tr>
<tr>
<td>Onset to treatment, h</td>
<td>14,209</td>
<td>...</td>
<td>5.6 [4.0, 9.0]</td>
</tr>
<tr>
<td>Type of stroke</td>
<td>12,212</td>
<td>Ischemic=13,029, intracerebral hemorrhage=1202</td>
<td>...</td>
</tr>
<tr>
<td>Barthel Index at 3 months</td>
<td>6284</td>
<td>...</td>
<td>85 [45, 100]</td>
</tr>
<tr>
<td>NIHSS at 3 months</td>
<td>2244</td>
<td>...</td>
<td>4.0 [1, 10]</td>
</tr>
<tr>
<td>SSS at 3 months</td>
<td>7701</td>
<td>...</td>
<td>48 [31, 56]</td>
</tr>
<tr>
<td>mRS at 3 months</td>
<td>5498</td>
<td>...</td>
<td>2.0 [0, 4]</td>
</tr>
<tr>
<td>Mortality at 3 months</td>
<td>12,729</td>
<td>Dead=2739</td>
<td>...</td>
</tr>
</tbody>
</table>

IQR indicates interquartile range; NIHSS, National Institutes of Health Stroke Scale; SSS, Scandinavian Stroke Scale; and mRS, modified Rankin Scale.

**TABLE 3. VISTA Trial Contents**

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>A20</td>
<td>Ancrod</td>
</tr>
<tr>
<td>STAT</td>
<td>Ancrod</td>
</tr>
<tr>
<td>ESTAT33</td>
<td>Ancrod</td>
</tr>
<tr>
<td>CMZ000920</td>
<td>Clomethiazole</td>
</tr>
<tr>
<td>ECASSI21</td>
<td>Alteplase</td>
</tr>
<tr>
<td>ECASSII22</td>
<td>Alteplase</td>
</tr>
<tr>
<td>GAIN Americas23</td>
<td>Gavestinel</td>
</tr>
<tr>
<td>GAIN International24</td>
<td>Gavestinel</td>
</tr>
<tr>
<td>IMAGES25</td>
<td>Magnesium sulfate</td>
</tr>
<tr>
<td>INT-1326</td>
<td>Lubeluzole</td>
</tr>
<tr>
<td>INT-5</td>
<td>Lubeluzole</td>
</tr>
<tr>
<td>INT-9</td>
<td>Lubeluzole</td>
</tr>
<tr>
<td>INWEST27</td>
<td>Nimodipine</td>
</tr>
<tr>
<td>SELFOTEL_0726</td>
<td>Selfotel</td>
</tr>
<tr>
<td>SELFOTEL_1028</td>
<td>Selfotel</td>
</tr>
<tr>
<td>ASK29</td>
<td>Streptokinase</td>
</tr>
<tr>
<td>TAIST30</td>
<td>Tinzaparin</td>
</tr>
<tr>
<td>TRUST31</td>
<td>Nimodipine</td>
</tr>
<tr>
<td>STICH32</td>
<td>Surgery for intracerebral hemorrhage</td>
</tr>
<tr>
<td>mRECT</td>
<td>Repinotan</td>
</tr>
<tr>
<td>NINDS4</td>
<td>Tissue-type plasminogen activator</td>
</tr>
</tbody>
</table>
Data sets that are used in proposed analyses are compiled on the basis of data availability; data from single or identified trials are not released without prior consent of the principal investigators of these trials. Additionally, investigators are asked to identify named variables that are essential to their analyses, and subsequent data sets are compiled by a third party with no vested interest in the proposed study. This eliminates selection bias. VISTA trials include positive, neutral, and negative trials, but because the data of interest are retained control over dissemination of their data. In particular, these investigators are able to veto an analysis that would inadvertently reexamine and reveal treatment effect within their trial; in practice, such issues would likely be resolved by discussion and through independence of the statistical group.

Data from the nascent VISTA were used to develop the forced allocation system that was used to achieve an average onset-to-treatment time of <4 hours in the SAINT I trial. Currently, VISTA has 14 ongoing projects involving natural history data that may inform future trials. Questions under investigation include the incidence of congestive heart failure after index stroke in placebo-treated patients to provide guidance on the use of fluids early after stroke. VISTA is also involved in the early stages of a collaborative clinical trial. The resource will be used to provide matched historical comparator data for patients participating in a device trial. Other areas of investigation include the incidence of serious adverse events between 1 and 3 months after index stroke, with an aim to examine the feasibility and validity of using earlier follow-up periods in trial practice. An examination of electrocardiographic data from VISTA has also recently been completed.

In addition to VISTA, other databases are available to carry out analyses, such as the German Stroke Databank and the Database of the German Stroke Unit Register Study Group. Similarities exist in principle between the German Stroke Databank and VISTA. The German Stroke Databank is a multicenter, hospital-based registry of stroke patients who were registered between 1998 and 1999. It has been used as a resource for epidemiology, etiology, management, and outcome in stroke patients. VISTA has similar aims, but it includes specific subsets of patients who have been enrolled.
in international clinical trials of various therapies. The international relevance of the VISTA data, the larger sample, and the concentration on trial-eligible patients are unique but complementary features. Certain Cochrane Review groups also hold individual patient data for meta-analysis purposes: unlike those groups, VISTA does not plan for or permit examination of treatment effects, nor are the data restricted to a single trial topic. Again, the meta-analysis groups provide complementary opportunities; VISTA is distinct through encouraging data sharing and having a mechanism for handling external proposals.

Editors of reputable medical journals will no longer accept manuscripts of trials that have not been registered in an open database and for which the authors have not had access to the complete data. Many institutional review boards or national ethics committees apply similar rules. There can be little prospect of harm and substantial potential for universal gain from lodging trial data for at least the control group in a resource that will be used to improve future research and clinical care for the participating patient community. Some national grant-awarding bodies, such as the UK Medical Research Council, expect completed trial data to be available to their community. VISTA provides a mechanism for securely lodging, maintaining, and accessing such data for approved purposes. Perhaps it is time that registration of stroke trial data within VISTA or a similar resource should also be mandatory.

Appendix

VISTA Collaborators

M. Ali (University (Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary Glasgow, Glasgow, UK); P.M.B. Bath (Centre Institute of Neuroscience, University of Nottingham, Nottingham, UK); J. Curram (Bayer Plc, Newbury, Berkshire, UK); S.M. Davis (Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia); H.C. Diener (Department of Neurology, University of Essen, Essen, Germany); G.A. Donnan (Neurology, University of Melbourne, Melbourne, Australia); M. Fisher, (Department of Neurology, University of Massachusetts Medical School, Worcester, Mass); B.A. Gregson (Department of Neurosurgery, Newcastle University, Newcastle General Hospital, Newcastle, UK); J. Grotta (University of Texas at Houston Medical School, Houston, Tex); W. Hacke (Department of Neurology, University of Heidelberg, Heidelberg, Germany); M.G. Hennerici (Department of Neurology, Universitätsklinikum Mannheim, University of Heidelberg, Heidelberg, Germany); M. Hommel (Joseph Fourier University, Grenoble, France); M. Kaste (Department of Neurology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland); P. Lyden (University of California and Veterans Administration, San Diego, Calif); J.R. Marler (National Institute of Neurological Disorders and Stroke, Bethesda, Md); R.L. Sacco (Departments of Neurology and Epidemiology, Columbia University, New York, NY); P. Teal (University of British Columbia, Vancouver, Canada); N.G. Wahlgren (Karolinska Hospital, Stockholm, Sweden); S. Warach (National Institute of Neurological Disorders and Stroke, Bethesda, Md); C.J. Weir (Robertson Centre for Biostatistics, Glasgow, UK); S. Kean (Robertson Centre for Biostatistics, Glasgow, UK); J. Ford (Robertson Centre for Biostatistics, Glasgow, UK); and K.R. Lees (University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary Glasgow, UK).

VISTA Steering Committee


Acknowledgments

We would like the thank all VISTA collaborators who contributed data from previous clinical trials so that we could establish this database and also the staff at the Robertson Centre for Biostatistics for their invaluable help in organizing and managing the data.

Disclosures

VISTA is a not-for-profit collaboration of researchers from academia and commercial organizations. The VISTA Steering Committee members have each contributed to the organization of contributing trials, and where these involved industry support, they have acknowledged that within the original publications. No author has any additional conflict of interest to declare in relation to this work, which was not externally supported.

References


